Fesoterodine for amelioration of Autonomic Dysreflexia (AD) following Spinal Cord Injury (SCI)

PURPOSE OF THIS STUDY:

This study will be investigating the effects of fesoterodine on AD in patients with SCI. The goal of the study is to examine the effect of increasing daily use of fesoterodine on episodes of high blood pressure triggered by urinary bladder contractions.

WHO CAN PARTICIPATE?

This study is open to adults (18-55 years of age) with chronic (>1 year post injury) traumatic SCI at or above the sixth thoracic (T6) spinal segment with the hand function to perform clean intermittent catheterization (CIC) or who have access to a dedicated caregiver.

WHAT IS INVOLVED?

The study is a collaborative effort between a physiatrist (Dr. Krassioukov), urologists (Dr. Rapoport and Dr. Kavanagh) and a postdoctoral fellow (Dr. Walter) who have significant experience with AD and urinary function following SCI.

Eligible individuals will attend six visits at the site and have a follow-up telephone call following completion of the study. The expected duration of study participation for each individual will be 115 days (17 weeks). This does not included the screening period. Procedures/tests for this study involve urodynamic studies, blood pressure monitoring over 24 hours, and questionnaires before and after receiving study drug.

CONTACT INFORMATION:

Andrea Ramirez, Clinical Research Coordinator
Phone: 604.675.8856
Email: aramirez@icord.org

To learn more about this study, visit vchri.ca/participate

STUDY TIME/DURATION

November 2015 to June 2018

STUDY LOCATION

This study will take place at ICORD at the Blusson Spinal Care Centre
818 West 10th Avenue, Vancouver

PRINCIPAL INVESTIGATOR

Dr. Andrei Krassioukov
Professor, Department of Medicine, Physical Medicine & Rehabilitation, UBC
Associate Director & Scientist, ICORD
VCH Research Institute Affiliated Investigator

Health research changes lives.

Be part of the discovery.
vchri.ca/participate

Vancouver CoastalHealth Research Institute